the aid library

Key
Resources
Clinical
Guidelines
Women & Child
Health
Pharmacy &
Technologies
Public
Health
Capacity
Building
COUNTRIES
TOOLBOXES
- Conflict
- Zika
- TB
- Cholera
- HIV
- Polio
- Rapid Response
- Refugee
- Disability
- Specific Hazards
- Social Ethics
- Health Financing Toolbox

Middle East and North Africa
West and Central Africa
East and Southern Africa
South–East Asia Region
Western Pacific Region
Eastern Europe and Central Asia
Latin America and the Carribbean
Western and Central Europe
North America
South Sudan
Turkmenistan
Jamaica
Japan
Belgium
France
Maldives
Mauritius
Tunisia
Portugal
Spain
South Korea
Algeria
Azerbaijan
Belarus
French Guyana
Israel

Login
Register
English

Search database

Suggest new resources

Filter

33

Text search: fluvoxamine

Featured

Recommendations

2

New Publications

2

Language

English

29

French

3

Spanish

1

Document type

No document type

22

Guidelines

10

Manuals

1

Countries / Regions

Ethiopia

3

South Africa

2

Singapore

1

Latin America and the Carribbean

1

Global

1

Authors & Publishers

IACAPAP

10

World Health Organization WHO

6

et al.

3

B. Vitiello

2

J. Liu

2

J. M. Rey

2

M. Conceição do Rosário

2

National Department of Health, South Africa

2

P. Gomes de Alvarenga

2

R. S. Mastrorosa

2

T. T. Bella-Awusah

2

A. Figueroa

1

A. Ivanenko

1

A. Lachman

1

A. Locke, N. Kirst, C.G. Shultz

1

Academic Journal of Interdisciplinary Studies MCSER Publishing

1

American Academy of Child and Adolescent Psychiatry

1

American Academy of Family Physicians

1

Ana Figueroa, Cesar Soutullo, Yoshiro Ono & Kazuhiko Saito

1

Åsa Hammar and Guro Årdal

1

B.Bandelo, S. Michaelis, D. Wedekind

1

C. Soutullo

1

Centre for Addiction and Mental Health CAMH

1

Drug Administration and Control Authority (DACA) of Ethiopia

1

Eglantina Dervishi

1

Food, Medicine and Health care Administration and Control Authority of Ethiopia (FMHACA)

1

Food, Medicine and Healthcare Administration and Control Authority of Ethiopia

1

Journal of Clinical Medicine

1

Korn, D.A. and H.J. Shaffer

1

Lancaster, C.L., Teeters, J.B., Gros, D.F., Back, S.E.

1

Ministry of Health and Consumer Affairs, Agencia Laín Entralgo. Unidad de Evaluación de Tecnologías Sanitaria, Madrid

1

Ministry of Health, Singapore

1

NDoH South Africa

1

PAHO

1

Pan American Health Organisation PAHO

1

Patel, Vikram

1

Rector, N., D. Bourdeau, K. Kitchen, et al.

1

Royal College of Psychiatrists

1

S. Cortese

1

S. Seedat

1

T. D. Benton

1

U. Ramtekkar

1

World Health Organization

1

Y. Ono

1

Publication Years

2020-2026

7

2010-2019

20

2000-2009

6

Category

Countries

7

Clinical Guidelines

1

Key Resources

1

Toolboxes

Mental Health

23

COVID-19

6

Conflict

1

Pharmacy

1

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi ... th severe or critical COVID-19, and modifies previous recommendations for the neutralizing monoclonal antibodies sotrovimab and casirivimab-imdevimab in patients with non-severe COVID-19. more

Pharmacological interventions for anxiety disorders in children and adolescents

World Health Organization WHO World Health Organization (2012) C_WHO

Q 12: In children and adolescents with anxiety disorders, what is the effectiveness and safety, considering system issues in low- and middle-income countries, of using pharmacological interventions in non-specialist settings?

Management of Gambling Disorders

Ministry of Health, Singapore (2011) CC

MOH clinical practice guidelines

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Considerations on the Use of Antivirals, Monoclonal Antibodies, and Other Interventions for the Management of COVID-19 Patients in Latin America and the Caribbean

World Health Organization WHO; PAHO; et al. (2022) CC

May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently, ... the WHO and the PAHO recommend the use of corticosteroids, tocilizumab, baricitinib, and casirivimab e imdevimab (the latter in seronegative COVID-19 patients) and propose the use of sotrovimab, casirivimab/imdevimab, and molnupiravir in patients with non-severe illness who are at high risk for complications more

COVID-19 Treatment Guidelines

National Department of Health, South Africa (2022) CC

Updated Treatment Guidelines

Where there is no psychiatrist : a mental health care manual

Patel, Vikram Royal College of Psychiatrists (2003) C2

This book is a practical manual of mental health care for community health workers, primary care nurses, social workers and primary care doctors, particularly in developing countries.Helpful features include: over 50 illustrations and case studies, jargon-free explanations and descriptions, flow-cha ... rts on common clinical problems, and a practical guide to the use of psychiatric medicines and simple psychological treatments. Chapters 1, 9 and 10 can be found on the e-TALC CD-ROM number 2 (April 2003). See www.talcuk.org for details Links to Chapters 2 and 3 above. Printed copies of this book can also be obtained from the Royal College of Psychiatrists www.rcpsych.ac.uk/wnitp more

Treatment of anxiety disorders

B.Bandelo, S. Michaelis, D. Wedekind (2017) CC

Dialogues Clin Neurosci. 2017 Jun; 19(2): 93–107.

Separation Anxiety

A. Figueroa; C. Soutullo; Y. Ono; et al. IACAPAP (2012) C2

Anxiety disorders Chapter F.2

Depression in children and adolescents

J. M. Rey; T. T. Bella-Awusah; J. Liu IACAPAP (2015) C2

Mood disorders Chapter E.1 2015 edition

Troubles obsessionnels compulsifs chez l'enfant et l'adolescent

P. Gomes de Alvarenga; R. S. Mastrorosa; M. Conceição do Rosário IACAPAP (2012) C2

Troubles Anxieux Chapitre F.3 Edition en français Traduction : Alexis Revet Sous la direction de : Jean-Philippe Raynaud Avec le soutien de la SFPEADA

HIV/AIDS - Addressing the mental health needs of affected children and families

T. D. Benton; A. Lachman; S. Seedat IACAPAP (2013) C2

Psychatry & Pediatrics Chapter I.3

COVID-19 Guidelines Module 5 - Drug therapy

National Department of Health, South Africa NDoH South Africa (2021) CC

Clinical Practice Guideline for Treatment of Patients with Anxiety Disorders in Primary Care

Ministry of Health and Consumer Affairs, Agencia Laín Entralgo. Unidad de Evaluación de Tecnologías Sanitaria, Madrid (2010) C2

The purpose of the Clinical Practice Guideline for Treatment of Patients with Anxiety Disorders in Primary Care is to provide professionals with practical recommendations based on scientific evidence to assist in the detection and effective treatment of these disorders

Posttraumatic Stress Disorder: Overview of Evidence-Based Assessment and Treatment

Lancaster, C.L., Teeters, J.B., Gros, D.F., Back, S.E. Journal of Clinical Medicine (2016) CC

Abstract: Posttraumatic stress disorder (PTSD) is a chronic psychological disorder that can develop after exposure to a traumatic event. This review summarizes the literature on the epidemiology, assessment, and treatment of PTSD. We provide a review of the characteristics of PTSD along with associa ... ted risk factors, and describe brief, evidence-based measures that can be used to screen for PTSD and monitor symptom changes over time. In regard to treatment, we highlight commonly used, evidence-based psychotherapies and pharmacotherapies for PTSD. Among psychotherapeutic approaches, evidence-based approaches include cognitive-behavioral therapies (e.g., Prolonged Exposure and Cognitive Processing Therapy) and Eye Movement Desensitization and Reprocessing. A wide variety of pharmacotherapies have received some level of research support for PTSD symptom alleviation, although selective serotonin reuptake inhibitors have the largest evidence base to date. more

Cognitive functioning in major depression – a summary

Åsa Hammar and Guro Årdal (2009) CC

Front. Hum. Neurosci., 25 September 2009 | https://doi.org/10.3389/neuro.09.026.2009

Principios de uso de medicación psicotrópica en niños y adolescentes

B. Vitiello IACAPAP (2016) C2

Introducción Capítulo A.7 Edición en español Editor: Juan José García-Orozco Traducción: Juan José García-Orozco y Carlos González Vivas Revisor de traducción: Laura Borredá Belda

Post Traumatic Stress Disorder in Children Sexsual Abuse

Eglantina Dervishi Academic Journal of Interdisciplinary Studies MCSER Publishing (2015) CC

The aim of this study is to research deeply on the post-traumatic stress disorder in sexually abused children. Proving the presence of forms of the disorder in children and the their treatment mode will be in the center of the study. The methods used to conduct this study will be a literature review ... on the focused issue referring to reviews of articles which focus on the defined peer group. For the purpose we have selected only articles focusing on sexually abused children treated for post-traumatic stress disorder. The results of the study reveal that all forms of abuse could bring consequences on children, even more, posttraumatic stress is the language with which the victims communicate their sorrow in the most typical mode. Sexual abuse as one of the major forms of abuse, is among the most severe which cause irreversible consequences over a category of children. In conclusion we can assume that post-traumatic stress in sexually abused children might appear through the most severe forms of psychiatric and psychological symptoms and for the recovery and rehabilitation of the child in many cases the pharmacological treatment seems as the best choice for the child. more

List of Medicines for Community Pharmacy, Ethiopia (LMCP)

Food, Medicine and Health care Administration and Control Authority of Ethiopia (FMHACA) (2012) C1

Fourth Edition

List of Medicines for Ethiopia

Food, Medicine and Healthcare Administration and Control Authority of Ethiopia (2010) C1

6th edition

1
2
›
»

Create your own
Login

Home
Contact
Data privacy
Legal notice
FAQ
About
Sitemap

A Project by

medbox @ 2026